Agreement provides PhaseBio with $20 million upfront payment and eligibility to receive up to $245 million in development and commercial milestones in addition to tiered double digit royalties on sales Collaboration reinforces global bentracimab opportunity Establishes accessibility to bentracimab, if approved, for the largest pool of ticagrelor patients in the […]